Zeruesenay Desta - Concepedia

Author

Zeruesenay Desta

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Desta Zeruesenay, Jones, David R., Magrinat, Gustav, Raab, Rachel E., Z DESTA, Z Desta, Z. Desta, ZERUESENAY DESTA, Zeruesenay Desta, Zeruesenay Desta,

265

Publications

12.2K

Citations

H-Index

147

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine University of Michigan Georgetown University Johns Hopkins University

About

Zeruesenay Desta is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	41	2.5K
2	Health Sciences	5	5	155
3	Natural Sciences	3	3	111
4	Language Studies	2	2	36
5	Nursing	2	2	58

Zeruesenay Desta

122

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment Yan Jin, Zeruesenay Desta, Vered Stearns, JNCI Journal of the National Cancer Institute	2005	931
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes Matthew P. Goetz, James M. Rae, Vera J. Suman, Journal of Clinical Oncology	2005	778
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 Zeruesenay Desta, Bryan A. Ward, Nadia Soukhova, Journal of Pharmacology and Experimental Therapeutics	2004	641
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity Bryan A. Ward, J. Christopher Gorski, David R. Jones, Journal of Pharmacology and Experimental Therapeutics	2003	591
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Matthew P. Goetz, Stacey K. Knox, Vera J. Suman, Breast Cancer Research and Treatment Endocrine-related CancerMedicineGynecologyAdjuvant TamoxifenBreast Cancer	2006	550
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Young Chai Lim, Zeruesenay Desta, David A. Flockhart, Cancer Chemotherapy and Pharmacology Breast OncologyAnti-estrogenic EffectsMedicineBreast Cancer CellsPharmacology	2005	294
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing John J. Lima, Cameron D. Thomas, Julia M. Barbarino, Clinical Pharmacology & Therapeutics	2020	281
Significant Effect of Polymorphisms in<i>CYP2D6</i>and<i>ABCC2</i>on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients Kazuma Kiyotani, Taisei Mushiroda, Chiyo K. Imamura, Journal of Clinical Oncology	2010	223
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism<i>in Vitro</i> Zeruesenay Desta, Bryan A. Ward, Julia Blievernicht, Pharmacogenomics	2007	223
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A Zeruesenay Desta, Nadia Soukhova, David A. Flockhart Antimicrobial Agents and Chemotherapy	2001	178

Page 1